Charles Elliott Sigal is Director at Vir Biotechnology, Inc. (VIR). They have made 5 open-market trades across 2 companies since 2016, most recently 2026-05-27.
CIK 0001661908
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
5 open-market purchases totalling $338K since 2016, never a sale. Across 5 scored buys the stock is down 9.3% at ninety days, and 15.3 points behind the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 100% | 60% | 20% |
| Avg Move | +5.4% | +2.7% | -9.3% |
| Alpha | +3.8% | -1.0% | -15.3% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VIR | BUY | 2023-03-01 | 2023-03-02 | $22.73 | $57K | +3.1% | +2.0% | +16.9% |
| VIR | BUY | 2023-01-05 | 2023-01-09 | $24.96 | $62K | +6.1% | +4.1% | -8.7% |
| VIR | BUY | 2023-01-03 | 2023-01-05 | $25.43 | $127K | +2.7% | +16.9% | -9.0% |
| ADAP | BUY | 2016-05-19 | 2016-05-19 | $1.56 | $23K | +5.6% | -5.8% | -25.1% |
| ADAP | BUY | 2016-05-16 | 2016-05-18 | $1.53 | $69K | +9.6% | -3.6% | -20.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.